Gastric cancer cells have an altered pattern of gene expression which helps them hide from the immune system.
Proteins involved in RNA editing could potentially be used as biomarkers to detect gastric cancer at an early stage, a study finds.
Varlitinib previously received orphan drug designation for cholangiocarcinoma in August 2015.
Duplication of the SHP2 binding site in the H. pylori protein CagA increases its binding by a hundred times, elevating the risk of gastric cancer.
Scientists have identified a fusion gene that causes epithelial damage and increased cell invasiveness, predisposing carriers to gastric cancer.